BioPharma Resources

Drug Trial Radar · NCT04534075

Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial

Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

354

Actual

Start

Sep 2, 2020

Primary completion

Sep 14, 2024

Study completion Sep 14, 2024

Sponsor

Lead sponsor
Sahlgrenska University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Research Council; VGregion; The Sjöberg Foundation
First posted
Sep 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators hypothesize that an increase in dietary fiber intake during radiation therapy may provide better long-term intestinal health for the cancer survivor. If the hypothesis is not correct, the increased intake may only mean an increase in acute side effects. All participants are advised to consume at least 16 g of dietary fiber/day via food. In addition, participants are invited to take capsules that together contain either 5.5 g of dietary fiber from psyllium husk or placebo.

Conditions

  • Malignant Neoplasm
  • Malignant Neoplasm of Rectum
  • Malignant Neoplasm of Anus
  • Malignant Neoplasm of Urinary Bladder
  • Malignant Neoplasm of Cervix
  • Malignant Neoplasm of Ovary
  • Malignant Neoplasm of Prostate
  • Malignant Neoplasm of Large Intestine
  • Malignant Neoplasm of Colon
  • Gynecologic Cancer

Interventions

  • Capsules containing either dietary fiber or placeboBiological

    The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sign of inflammation i bloodTime frame: One month after the end of radiotherapy
  2. Intensity of the urgency syndromeTime frame: One year after the end of radiotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jubileumskliniken, Sahlgrenska University Hospital

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.